Revolution Medicines Inc. (RVMD)
FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer
Revolution Medicines' FDA filing for daraxonrasib in metastatic pancreatic cancer enters an accelerated review program, bringing its first commercial product closer.
EMA fast-tracks review of Revolutions' experimental pancreatic cancer pill
The European Medicines Agency said on Tuesday it has begun a rolling review of Revolution Medicines' experimental treatment for patients with metastatic pancreatic cancer.
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib
Revolution Medicines launches a phase III study of zoldonrasib plus chemotherapy in first-line metastatic PDAC harboring RAS G12D mutations.
Revolution Medicines: Strong Data, Big Market (Rating Upgrade)
Revolution Medicines is upgraded to buy as Daraxonrasib delivers practice-changing Phase 3 data in pancreatic ductal adenocarcinoma (PDAC). RVMD's $4B pro forma liquidity supports over two years of aggressive clinical expansion, with cash burn focused on value-driving trials and regulatory submissions. Daraxonrasib's Phase 3 results show a 60% reduction in risk of death and doubled median overall survival in metastatic PDAC, supporting a multi-billion-dollar opportunity.
Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?
Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?
RVMD Stock Rises on Detailed Results From Pancreatic Cancer Study
Revolution Medicines jumps after detailed phase III data show daraxonrasib cuts death risk by 60% and doubles median survival in treated pancreatic cancer.
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug
U.S. cancer centers are scrambling to enroll patients in an early access program for a highly promising pancreatic cancer drug from Revolution Medicines while they await what they hope will be a speedy FDA approval.
RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense View
Revolution Medicines posts a wider Q1 loss and raises its 2026 expense outlook as R&D and commercial prep costs climb.
There's a Revolution in Cancer. But Can Big Pharma Afford It?
Revolution Medicines' stock has surged on the promise of a pancreatic-cancer drug. With any deal to buy the firm looking unlikely, investors should be prepared for the long haul.
RVMD Stock Rallies 41% on Positive Phase III Pancreatic Cancer Data
Revolution Medicines jumps 41% as phase III data show daraxonrasib boosts survival in metastatic PDAC, paving the way for global regulatory filings.
How This Biotech Stock Skirted Today's Selloff
Revolution Medicines Inc (NASDAQ:RVMD) stock is brushing off the broad market selloff this morning, last seen up 35.5% to trade at $131.35, and earlier hitting a record high of $135.81.
Revolution Medicines surges 38% as pancreatic cancer drug shows breakthrough
Shares of Revolution Medicines surged sharply on Monday after the company reported positive results from a late-stage trial of its experimental pancreatic cancer drug, raising hopes for a potential breakthrough in one of the deadliest forms of the disease. The stock climbed 38% after the opening bell, extending gains to 69% since the start of the year.
